Charles River has announced its proposed acquisition of PathoQuest. Since 2016, Charles River and PathoQuest have partnered to provide clients with access to PathoQuest’s NGS solutions, and the proposed acquisition is expected to strengthen Charles River’s existing Biologics Testing capabilities by adding rapid, in vitro GMP and non-GMP testing solutions.
PathoQuest’s innovative NGS approach supports Charles River’s Alternative Methods Advancement Project (AMAP) initiative by utilizing new approach methodologies (NAMs) to replace animal use in viral safety workflows, while also accelerating clients’ quality-control testing timelines and the overall biologics development process.
To know more
